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Purpose: The logistics of conducting double-blinded phase III clinical trials with participants residing in
remote locations are complex. Here we describe the implementation of an interventional trial for the
prevention of late cytomegalovirus (CMV) disease in hematopoietic cell transplantation (HCT) subjects in
a long-term follow-up environment.
Methods: A total of 184 subjects at risk for late CMV disease surviving 80 days following allogeneic HCT
were randomized to receive six months of valganciclovir or placebo. Subjects were followed through day
270 post-transplant at their local physician's ofﬁce within the United States. Anti-viral treatment in-
terventions were based on CMV DNAemia as measured by polymerase chain reaction (PCR)
(>1000 copies/mL) and granulocyte colony stimulating factor (G-CSF) was prescribed for neutropenia
(absolute neutrophil count (ANC < 1.0  109 cells/L). Blood samples for viral testing and safety moni-
toring were shipped to a central laboratory by overnight carrier. Real-time communication was estab-
lished between the coordinating center and study sites, primary care physicians, and study participants
to facilitate starting, stopping and dose adjustments of antiviral drugs and G-CSF. The time required to
make these interventions was analyzed.
Results: Of the 4169 scheduled blood specimens, 3832 (92%) were received and analyzed; the majority
(97%) arriving at the central site within 2 days. Among subjects with positive CMV DNAemia (N ¼ 46),
over 50% received open label antiviral medication within one day. The median time to start G-CSF for
neutropenia was <1 day after posting of laboratory results (range 0e6; N ¼ 38). Study drug dose ad-
justments for abnormal renal function were implemented 203 times; within one day for 48% of cases and
within 2 days for 80% of cases.
Conclusion: Complex randomized, double-blind, multicenter interventional trials with treatment de-
cisions made at a central coordinating site can be conducted safely and effectively according to Good
Clinical Practice (GCP) guidelines over a large geographic area.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).isease Division, Fred Hutch-
4-100, PO Box 19024, Seattle,
kh).
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Because many patients are managed by their local primary care
providers after hematopoietic cell transplantation (HCT), often
distant from the transplant center, timely communication and co-
ordination of care in a clinical trial context according to Good
Clinical Practice (GCP) standards can be challenging. The compli-
cated logistics of managing a trial requiring real-time changes in
patient care based on laboratory results from a distance means that
such studies are rarely, if ever done. Indeed the paucity of high-
quality treatment and prevention studies in this setting has
plagued the ﬁeld for decades. We recently reported the ﬁndings
from an investigator-initiated, multicenter, double-blind placebo-
controlled, randomized Phase III trial comparing valganciclovir
prophylaxis to polymerase chain reaction (PCR)-guided preemptive
therapy for the prevention of late cytomegalovirus (CMV) disease in
post-allogeneic HCT patients surviving at least 80 days from
transplant [1], which was speciﬁcally designed to allow for the
expansion of the study drug label to include prophylactic use. The
study demonstrated that complex clinical trials utilizing both pri-
vate and academic-based care settings can be successfully carried
to fruition and provided a model for the cooperation necessary for
the successful completion of the trial. Here we present the speciﬁcs
that enabled this long-term, double-blinded phase III clinical trial
to be successfully conducted across 36 U.S. states with real-time
treatment and dose adjustment of study medications based on
laboratory monitoring.
2. Methods
2.1. Trial design
The detailed design of the clinical trial is reported elsewhere [1].
Brieﬂy, a multi-center randomized, double-blind, placebo-
controlled study of valganciclovir for the prevention of late CMV
infection was conducted in CMV seropositive subjects undergoing
allogeneic HCT between 2001 and 2008. Seven sites participated in
this study with the Fred Hutchinson Cancer Research Center (Fred
Hutch) as the coordinating center. Over the course of the study, 184
subjects were randomized and formed the intent-to-treat popula-
tion. Randomization to receive study drug (valganciclovir or pla-
cebo) occurred between day 80 and day 120 post HCT
(Supplementary Fig. 1). The active study period during which study
drug was administered and real-time decisions were made
occurred between randomization and day 270 post-transplant.
2.2. Communication between sites, primary providers and
participants
Maintaining communication between the coordinating site and
primary physicians was critical to the success of this study and to
ensuring timely interventions. Subjects were tested onceweekly by
PCR for CMV DNA in plasma, neutropenia (absolute neutrophil
count (ANC) < 1.0  109 cells/L) and renal insufﬁciency (serum
creatinine >2.5 mg/mL). Blood was drawn at the subject's local
medical facility and shipped overnight (Federal Express) using pre-
paid packages and study-provided kits to the coordinating center
for testing at the University ofWashington clinical laboratories. The
primary care provider for each patient was contacted by site
personnel with laboratory results as they became available (Fig. 1).
Monthly contact with the subject during the treatment phase was
maintained by the study coordinator at the local sites and consisted
of status checks of CMV infections, other infections, hospitalization,
adverse events, medication history, study drug compliance and any
requests for drug supply or laboratory supplies. Data, includingclinical and laboratory records, were maintained in a secure online
database. Hardcopies of case report forms were also available for
review.
2.3. Metrics evaluated
To evaluate the logistical aspects of conducting an interven-
tional trial for the prevention of late CMV disease in HCT subjects in
a long-term follow up environment, we examined the geographic
distribution of subjects, time required to receive overnight ship-
ment of blood specimens and the turnaround time for clinical in-
terventions based on laboratory results.
2.4. Interventions
We analyzed the performance characteristics of several key in-
terventions. Clinical interventions consisted of (a) start of pre-
emptive antiviral treatment for a positive CMV quantitative PCR
result  1000 IU/mL (b) interruption of study drug administration
and start of granulocyte colony stimulating factor (G-CSF) for any
neutropenic episode deﬁned by ANC < 1.0  109 cells/L and (c)
adjustment of study medication dose based on renal function.
Subjects were monitored on a weekly basis with plasma CMV DNA
PCR testing and complete blood count (CBC) with differential and
blood chemistry panels through day 270.
2.4.1. Initiation of preemptive antiviral treatment for a positive CMV
DNAemia
If subjects developed PCR DNAemia (>1000 copies/mL) or CMV
disease (reactivation of previously latent infection or newly ac-
quired infection with evidence of organ involvement), they were
treated with intravenous ganciclovir (5 mg/kg) or open-label val-
ganciclovir (900 mg) twice daily for one week or until DNAemia
declined followed by open-label once daily valganciclovir
(900 mg); foscarnet (90 mg/kg twice daily) was used instead if
indicated due to neutropenia. Intravenous (IV) ganciclovir was
given for initial treatment of CMV disease and in situations when
no oral medication could be administered. In January 2004, the
protocol was modiﬁed to allow the use of open label valganciclovir
as an alternative to IV ganciclovir for the treatment of CMV reac-
tivation to prevent possible treatment delays associated with the
logistics of IV therapy. Patients were given a supply of valganci-
clovir and instructed by the study coordinator to discontinue study
drug and start open-label treatment when CMVDNAemia exceeded
the threshold. These patients were subsequently monitored by PCR
and retreated if CMV tests resulted positive through day 270. Fos-
carnet 60 mg/kg IV twice daily induction for at least 1 week was
given for patients with neutropenia, followed by 90 mg/kg main-
tenance daily until the PCR result was negative.
2.4.2. G-CSF initiation for neutropenia
Neutrophil counts were monitored while subjects received
study drug through day 270. If the ANC dropped below
1.0  109 cells/L, study drug was held, and G-CSF could be pre-
scribed per physician discretion based on ANC levels. G-CSF was
recommended until the ANC was >1.0  109 cells/L. The protocol
allowed up to 14 days of G-CSF support at which time a bone
marrow biopsy was recommended to establish a diagnosis. During
periods of neutropenia, monitoring of ANC was performed locally
every other day and the results were faxed to the enrolling site.
Blood draws for ANC were also shipped to the central site twice
weekly while the patient was neutropenic. In January 2004, the
protocol was amended to standardize the use of G-CSF for the
treatment of neutropenia at an ANC < 1.0  109 cells/L in all
participants.
Fig. 1. Study communication. CMV ¼ cytomegalovirus; PCR ¼ polymerase chain reaction; ANC ¼ absolute neutrophil count; G-CSF ¼ granulocyte colony stimulating factor.
Table 1
Patient characteristics (n ¼ 184).
Characteristic Value
Age (median) 49.70 years
Gender
Male 104 (56.52%)
Female 80 (43.48%)
Race
White 165 (90.76%)
Black 1 (0.54%)
Asian/Paciﬁc Islander 7 (3.80%)
Native American 1 (0.54%)
Other/Unknown 8 (4.35%)
Ethnicity
Hispanic 5 (2.72%)
Non-Hispanic 176 (95.65%)
Unknown 3 (1.63%)
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Blinded study drug (valganciclovir, placebo) and open label
drugs (ganciclovir, valganciclovir, foscarnet) were adjusted based
on the patient's estimated creatinine clearance according to
manufacturer recommendations.
2.5. Statistical analysis
We compared the time from the ﬁrst CMV PCR positive test to
start of antiviral therapy, as well as time between discovery of
neutropenia and G-CSF administration, between the study period
before and after January 2004, when anti-viral medication and G-
CSF protocols changed, using the Mann-Whitney U test. P values
less than 0.05 were considered signiﬁcant.
3. Results
3.1. Geographical distribution of subject locations
A total of 184 study participants across 141 cities and 5 time
zones were randomized and received at least one dose of study
drug. Demographics are shown in Table 1, and geographic distri-
bution is displayed in Fig. 2.
3.2. Turnaround time of blood samples delivered by overnight
shipment
Out of 4169 expected surveillance samples, a total of 3832 CBCs
(92%) with differential, blood chemistry panels and CMV DNA
samples for PCR were received and processed during the study
period. Reasons for missed samples were not collected or recorded
systematically. In general, samples were missed due to hospitali-
zation, dependent care responsibilities, subject health issues and
reentry of the subjects into employment and other responsibilities
following recovery. Travel was also a possible reason for missing a
sample, but we made every effort to help subjects locate clinics for
blood drawswhen theywere away fromhome and provided kits for
the draws. Transit time was deﬁned as the time of collection from
the subject to the time of the sample being received by the coor-
dinating center. A total of 158 subjects (86%) were collected at off-site locations (deﬁned as locations other than the coordinating site,
Seattle) and delivered by overnight carrier. Among all samples, 63%
were received within 1 day, an additional 34% within 2 days, and
the remaining 3% more than 2 days after collection, with a median
transfer time of 1 day (range 0e7 days) (Fig. 3a). Most samples
(>85%) were drawn and shipped Monday to Wednesday, as
requested. Samples were delayed past 48 h due to shipment on a
Friday or Saturday, when extreme weather interfered with over-
night couriers, or due to non-Monday federal holidays. Delays were
not a result of federal holidays onMondays or the terrorist attack of
September 11, 2001 and subsequent alterations to air travel in the
US.
3.3. Start of preemptive antiviral treatment
Preemptive treatment for CMV was initiated 46 times (N ¼ 36
patients) a median of 1 day (range 0e28) after the CMV DNAemia
above the threshold was detected. Although there was a noticeable
delay of 3 or more days in treating 7% of the episodes, no CMV
disease occurred directly related to the delay. One patient was
treated with foscarnet as the initial treatment due to neutropenia
that started at the same time as CMV reactivation; treatment began
within 2 days. We compared time-to-treat after receipt of CMV PCR
Fig. 2. Geographical distribution of subjects on study in the United States. Counts within each state represent the number cities with individuals enrolled throughout the course of
the study. Star indicates the location of the coordinating center in Seattle, Washington. Dots indicate location of participating centers (University of Texas MD Anderson Cancer
Center, Houston, Texas, Memorial Sloan Kettering Cancer Center, New York, New York, University of Florida, Gainesville, Florida, Mayo Clinic, Rochester, Minnesota, City of Hope
National Medical Center, Duarte, California, University of Michigan, Ann Arbor, Michigan, and Duke University, Durham, North Carolina).
Fig. 3. a. Elapsed time between blood collection and specimen receipt at coordinating center. Median elapsed time was 1 day (range: 0e7 days) (N ¼ 3832). b. Elapsed time to
treatment initiation in response to CMV PCR positive result stratiﬁed based on original protocol and modiﬁed protocol initiated on 1 January 2004. Patients were given a supply of
valganciclovir and instructed by the study coordinator to discontinue study drug and start open-label treatment when CMV DNAemia exceeded 1000 IU/mL. One patient expe-
rienced an extended delay of 28 days due to concern for possible relapse of primary disease. (N ¼ 46 episodes in 36 patients). CMV ¼ cytomegalovirus; PCR ¼ polymerase chain
reaction.
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for treatment with oral valganciclovir as opposed to intravenous
ganciclovir and found no difference (Fig. 3b; p ¼ 0.65 for all epi-
sodes; p ¼ 0.51 for ﬁrst episode per patient only).3.4. Start of G-CSF for neutropenia
Neutrophil counts were monitored by study personnel. We
compared those treated prior to January 2004, when G-CSF was
only recommended but not an integral part of the protocol, to those
treated after the protocol was amended to include routine
administration of G-CSF. The standardization of G-CSF treatment
led to increased use of G-CSF in the post-modiﬁcation valganci-
clovir group (11% of patients pre-modiﬁcation vs. 27% post-
modiﬁcation) [1], but did not affect the time to start therapy.
Time to start G-CSF for an ANC < 1.0  109 cells/L was the same
before and after protocol modiﬁcation (p ¼ 0.98 for all episodes;
p ¼ 0.88 for ﬁrst episode per patient only), and occurred within 1
day in 71% and 2 days in an additional 18% of episodes (Fig. 4a).
Study drug was discontinued when the patients becameneutropenic; G-CSF was administered for neutropenia as described
above. The median time from identiﬁcation of neutropenia to
discontinuation of study drug was 1 day (range 0e6), and 80% of
the time study drug was discontinued on the same day of the result
or within 1 day (Fig. 4b). Five of the 7 instances where study drug
was not stopped until 3e4 days after the identiﬁcation of neu-
tropenia involved patients located in a time zone 3 h ahead of the
coordinating center, so that notiﬁcation to the primary care pro-
vider to stop study drug was not made until the morning after
neutropenia was found.3.5. Dose adjustments of study drug
Ganciclovir or valganciclovir dose adjustment for renal function
was implemented 203 times within a median of 1 day (range 0e5)
upon obtaining the result. Of these renal adjustments, more than
80% occurredwithin 2 days (range 0e6 days; Fig. 4c), but 5% of dose
adjustments were not made until 4 days after the results were
available and 1.5% of adjustments were made 5 or more days after
the physician was notiﬁed. Of 37 cases with a delay of 2 days or
Fig. 4. a. Elapsed time from identiﬁcation of neutropenia (ANC < 1000/mm3) to start of G-CSF stratiﬁed on original protocol and modiﬁed protocol initiated on 1 January 2004
which made the use of G-CSF for treatment of neutropenia standard (N ¼ 38 episodes in 27 patients). ANC ¼ absolute neutrophil count; G-CSF ¼ granulocyte colony stimulating
factor. b. Elapsed time from neutropenia (ANC < 1000/mm3) to discontinuation of study drug (N ¼ 52). ANC ¼ absolute neutrophil count. c. Elapsed time prior to adjusting study
drug dose based on creatinine clearance results (N ¼ 203).
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days.4. Discussion
Despite the perception that conducting multicenter randomized
clinical trials according to GCP standards in the late period after
HCT is logistically infeasible, we demonstrate that it is possible to
overcome many of these challenges. We received 92% of scheduled
blood samples from 36 states without major problems. Only 3% of
samples were received more than 2 days after collection with an
overall median transfer time of 1 day. The transit time of all samples
met the recommended parameters of 72 h for the stability of CBC
specimens at 4 C [2]. Sample delivery was most affected by non-
Monday holidays and extreme weather conditions.
In the randomized trial [1], preemptive therapy was as suc-
cessful as prophylaxis in prevention of CMV disease but each had its
own challenges for management of patients. Preemptive therapy
required diligent follow-up to ensure viral testing was performed,
results were provided quickly, and treatment was provided quickly
when indicated. Prophylaxis with valganciclovir, a medication
associated with myelotoxicity and one that requires dose adjust-
ment in the setting of renal insufﬁciency, required diligent moni-
toring of ANC and serum creatinine; quick dose adjustment and the
provision of GCSF likely reduced the frequency and impact of severe
drug-related neutropenia.
Over 50% of subjects with CMV DNAemia greater than the
threshold were treated within one day of receipt of results. Given
that the doubling time of CMV is one to two days on average and
that immunosuppression plays a role in the in vivo replication dy-
namics [3], the ability to deliver care quickly is paramount,
although the doubling time may be longer late after HCT due to
partially reconstituted CMV-speciﬁc immunity.
The protocol was amended in January 2004 to allow for the use
of open label valganciclovir as preemptive therapy in place of IV
ganciclovir given the difﬁculty in rapidly coordinating the admin-
istration of IV therapy in an outpatient remote setting. Although
more patients received valganciclovir after the protocol change,time to receive the ﬁrst dose of preemptive therapy was not shorter
when patients had valganciclovir readily available at home. It may
be that time to treatment was impacted mostly by delays in noti-
ﬁcation from busy local doctors, rather than arranging for IV
administration. There were two outliers to starting therapy, one at
7 days and one at 28 days after receipt of positive PCR results. While
the time to begin treatment was prolonged in these cases neither of
these two subjects progressed to develop CMV disease. The 28 day
time lapse was due to the concern of relapsed malignancy, and the
7 day time lapse was likely due to communication issues between
the primary physician and the subject.
Neutropenia is an expected adverse event of ganciclovir and
valganciclovir; however, the exact incidence late after HCT is not
known. The use of G-CSF has been observed to reverse neutropenia
with a median time to reversal of 2 days in HIV-infected subjects
[4]. The majority of patients in our study started G-CSF within 2
days of discovery of neutropenia. Although more patients received
G-CSF once the protocol was modiﬁed to make administration
standard for neutropenia in January 2004, the change did not lead
to a more rapid start of the drug. Further, most patients dis-
continued study drug within 2 days of discovery of neutropenia.
Start of G-CSF and discontinuation of studymedicationwas delayed
in some cases due to the challenges presented by management of
the trial across multiple time zones. The reversal of severe neu-
tropenia appeared to be effective, as no statistically signiﬁcant
differences in invasive bacterial and fungal infections were seen
between the randomization groups [1,5,6].
Study drug dose adjustment for renal function was imple-
mented within a median of 1 day upon obtaining the result, but a
number of subjects requiring a dose adjustment were not informed
until 4 or 5 days after the results were available. This disappointing
delay did not have an obvious explanation, but may have been due
to differences in time zones and days of the week (Fridays). In any
case, the delay in dosage change only resulted in neutropenia in
one case. A recent survey of primary-care physicians reported
failure to inform the subject of their test results in 7.1% of all visits
[7]. Our study was able to ensure documentation and communi-
cation with subjects equal to and arguably better than global
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This study successfully implemented real-time management of
CMV preemptive treatment in a randomized, double-blinded, pla-
cebo-controlled setting away from comprehensive cancer centers.
The ability to quickly communicate with subjects and providers
across the United States was limited by the technology of the time.
When this study was initiated, telephone and fax were the standard
method used to communicate test results, with some email. Today,
email, text messaging and smart phone applications can rapidly
transmit results securely and remind subjects to take medications,
simplifying the logistics needed to conduct clinical trials with sub-
jects in remote locations [8]. People are easier to reach than everwith
less effort andexpenseon thepartof coordinators, asmanyelectronic
forms of communication can be automated and are growing in
acceptance. Even so, themonitoring of virologic and safety testing in
this study required signiﬁcant dedication fromstudy personnel, local
primary care providers and patients (Fig.1). Designated personnel to
perform vigilant and ongoing communication with subjects and
providers are needed to minimize late sample delivery, particularly
with regard to holidays and inclement weather, and allow thera-
peutic decisions to be made on a real-time basis.
This study has strengths and limitations. This study represents
the ﬁrst double blinded trial to successfully implement real-time
management of CMV preemptive treatment, and further demon-
strates prospective documentation of sample collection over time
covering a very large geographic and diverse area. One limitation is
that reasons for delays in study drug adjustment were not pro-
spectively collected on the study case report forms. Another limi-
tation is the inability to differentiate performance between patients
who were managed directly from site coordinators versus those
who were treated through remote providers.
Participation in long-term longitudinal interventional trials
with real time management of study medication in remote settings
provides subjects with access to expert medical professionals and
the latest therapies. It also helps to generate data of the highest
quality. This may be particularly relevant for studies of late com-
plications after HCT, such as chronic GVHD as well as pulmonary
and infectious complications [9]. In addition, patients may experi-
ence an increased sense of hope and meaning as a result of
contributing to studies offering better treatment for their disease
[10]. The prospect of enabling subjects to participate in a multi-
center study while being treated by their local physician represents
new options in healthcare delivery. Given the paucity of data on
turnaround times in oncology patients, this trial provides bench-
mark data for future interventions. Our results show that a ran-
domized double-blinded multicenter trial with subjects
geographically located miles from the coordinating center can be
conducted effectively, safely and according to GCP standards.
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